WRALtechwire.com logo

QuintilesIMS, Salesforce form 'molecule to market' data alliance

QuintilesIMS

Apr, 24 2017, 10:14 AM

QuintilesIMS is partnering with Salesforce to utilize cloud technology for what it calls a "molecule to market" data shop for pharmaceutical companies.

Financial terms of the deal, which was announced early Monday, were not disclosed. The companies said it covers several years and is international in scope.

“This Salesforce collaboration furthers our strategy of building our solutions on a foundation of intelligent, technology-standard platforms. Using this approach, as well as continuous updates provided by the platform providers, we can better focus on our areas of differentiation, which deliver the greatest value and benefit to our customers,” said Kevin Knightly, president, Information & Technology Solutions, QuintilesIMS.

“We believe this alliance with Salesforce has transformative potential for the life sciences industry as it will better equip and enable our customers to meet the clinical-to-commercial challenges they face as they move healthcare forward.”

Using cloud technology along with artificial intelligence and other tools from the Salesforce Platform, Quintiles says the new initiative aims to help clients:

“We are thrilled to align with QuintilesIMS (NYSE: Q) to digitally transform the important work of life sciences companies together,” said Keith Block, vice chairman, president and COO, Salesforce. “Building on the Salesforce Intelligent Customer Success Platform, QuintilesIMS will create solutions that empower life sciences firms to collaborate with providers and patients, in smarter and more predictive ways, throughout the clinical life cycle.”

QuintilesIMS operates dual headquarters in Durham and Danbury, CT.





Menu